Q1 Earnings Forecast for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($1.18) per share for the quarter. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ Q2 2025 earnings at ($1.08) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The business had revenue of $227.00 million during the quarter, compared to analysts’ expectations of $140.97 million. During the same quarter in the prior year, the company posted $0.12 earnings per share. The firm’s revenue was down 30.2% on a year-over-year basis.

Several other research analysts have also recently commented on the stock. Piper Sandler reduced their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday. StockNews.com cut shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Citigroup dropped their price target on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Ionis Pharmaceuticals Stock Performance

Shares of IONS opened at $32.33 on Monday. Ionis Pharmaceuticals has a 12 month low of $30.23 and a 12 month high of $52.34. The firm has a fifty day simple moving average of $33.65 and a 200 day simple moving average of $38.24. The stock has a market capitalization of $5.14 billion, a price-to-earnings ratio of -10.63 and a beta of 0.34. The company has a current ratio of 8.47, a quick ratio of 8.82 and a debt-to-equity ratio of 2.12.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC grew its stake in shares of Ionis Pharmaceuticals by 160.0% in the fourth quarter. Signaturefd LLC now owns 949 shares of the company’s stock valued at $33,000 after acquiring an additional 584 shares in the last quarter. Huntington National Bank grew its stake in shares of Ionis Pharmaceuticals by 193.5% in the fourth quarter. Huntington National Bank now owns 951 shares of the company’s stock valued at $33,000 after acquiring an additional 627 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Ionis Pharmaceuticals in the third quarter valued at about $40,000. Lindbrook Capital LLC grew its stake in shares of Ionis Pharmaceuticals by 183.8% in the fourth quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock valued at $36,000 after acquiring an additional 671 shares in the last quarter. Finally, Prospera Private Wealth LLC acquired a new stake in Ionis Pharmaceuticals during the third quarter worth about $42,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Brett P. Monia sold 33,445 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $32.63, for a total value of $1,091,310.35. Following the transaction, the chief executive officer now directly owns 207,396 shares of the company’s stock, valued at $6,767,331.48. This represents a 13.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eric Swayze sold 1,367 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $32.31, for a total transaction of $44,167.77. Following the completion of the transaction, the executive vice president now owns 48,017 shares in the company, valued at $1,551,429.27. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 110,609 shares of company stock valued at $3,564,867 over the last ninety days. 2.71% of the stock is currently owned by company insiders.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.